Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

ANPI, CRWE, ASTM, DLKM, CAVO - Stock Update From DrStockPick.com!

drstock-2-3

signup3m

Crown Equity Holdings Inc. (OTCBB:CRWE) is pleased to report its financial results for the nine month period ending September 30, 2010. Revenue for the nine months totaled $1,073,383 compared to $418,959 during 2009. The Company incurred an operating loss of $54,527 for the nine months ending September 30, 2010 compared to an operating loss of $36,923 during the same period in 2009. Net loss of $343,049 for the nine months ending September 30, 2010 compared to a net loss of $29,379 for the same period in 2009. The net loss in 2010 was attributed mostly to an unrealized loss of $307,544 on securities held by the Company.

"Our continued progress in operations including an operating profit of $7,251 during the last quarter shows a continued growth in our business," commented Kenneth Bosket, President and CEO of Crown Equity Holdings Inc. "Not only do our financial results show strong growth during this year but our continued investment in infrastructure will support our future growth," stated Bosket.

In other news, Crown Equity Holdings Inc. announced that its CEO and President, Kenneth Bosket, will appear on the Bill Chippas show on Dec. 30, 2010, at 3:30 pm Pacific Time.

To listen the interview, please visit www.wpsl.com

Crown Equity Holdings Inc., together with its digital network, currently provides electronic media services specializing in online publishing and Web sites, which bring together targeted audiences and advertisers that want to reach them. Crown Equity Holdings Inc. offers internet media-driven advertising services, which covers and connects a range of marketing specialties, as well as search engine optimization for clients interested in online media awareness.

********************************************

dlkm_logo

Douglas Lake Minerals (OTCBB:DLKM) is pleased to provide an update regarding its recently acquired Handeni Project which is located in the rapidly developing region of eastern Tanzania. Douglas Lakes’ 100% owned Handeni Project consists of four prospecting licenses covering approximately 800 km(2) which are directly adjacent to, and partly surround, Canaco Resources Inc’s (V.CAN) 200 km(2) Kilindi license which holds the Magambazi gold mineralization occurrence.

Douglas Lake Minerals is pleased to provide the results of the recent exploration program conducted on PLR PLR4973/2008, subsequently subdivided into four PL’s (PL6742/2010, PL6743/2010, PL6744/2010 and PL6779/2010), based on the outcomes of the first phase of the continuous exploration program conducted since 2008. This exploration phase included a fixed-wing aircraft flown aeromagnetic and radiometric survey at a line spacing of 200m and a height of 80m, subsequent interpretation of data and ground follow-up. The survey and interpretation was conducted according to internationally accepted standards by the Council for Geoscience, South Africa.

To take advantage of Tanzania’s rich natural resources, Douglas Lake Minerals has acquired two highly prospective gold projects in Tanzania. The Company has an experienced management and technical team of mining and investment professionals, and has made a strategic decision to focus exclusively on its two flagship properties – the recently purchased Handeni Gold Project and the Mkuvia Alluvial Gold Project.

The Handeni Gold Project comprises of four properties totaling 800 square kilometers and is located directly adjacent to Canaco Resources’ highly prospective Handeni Gold Project (TSX.V-CAN). This project will be explored under the guidance of the experienced geologist, Dr. Reyno Scheepers.

The Mkuvia Alluvial Gold Project comprises of four prospecting licenses covering a total area of 380 square kilometers and is located in the Nachingwea District, Lindi Region of the United Republic of Tanzania. This project is being developed by Douglas Lake Minerals’ joint-venture partners.

********************************************

Cavico Corporation (Nasdaq:CAVO) announced that its subsidiary, Cavico Bridge and Tunnel, has signed a construction contract with Electricity of Vietnam ("EVN"), a state-owned electricity company, for the Song Bung 2 Hydropower project. The contract is valued at $6 million and includes cost escalation clauses that may increase the revenues associated with the project.

Cavico Corp. provides construction and engineering services for civil construction infrastructure projects. It constructs tunnels, roads, highways, bridges, mines, and dams. The company also invests in hydropower electric plants, cement production plants, mining operations, and urban developments in Vietnam and Laos.

********************************************

Aastrom Biosciences, Inc. (Nasdaq:ASTM) announced that it has completed a public offering of 10,000,000 units at a price to the public of $2.25 per unit for an aggregate offering amount of $22.5 million, as on December 10, 2010.

Aastrom Biosciences, Inc., a regenerative medicine company, engages in developing antilogous cell therapies for the treatment of severe and chronic cardiovascular diseases. The company’s antilogous expanded cellular therapy technology uses single-pass perfusion to produce human cell products for clinical use.

********************************************

Angiotech Pharmaceuticals Inc. (Nasdaq:ANPI) announced that it and U.S. Bank National Association, as successor trustee under the Company's subordinated note indenture, dated as of March 23, 2006 (as amended, supplemented or otherwise modified from time to time, the "Subordinated Note Indenture"), at the direction of a majority of the holders of the Company's 7.75% Senior Subordinated Notes due 2014 (the "Subordinated Notes"), have executed a supplement to the Subordinated Note Indenture (the "Supplemental Indenture"). The Supplemental Indenture extends the grace period applicable to interest payments due on the Subordinated Notes from 90 days to 120 days before an event of default occurs.

Angiotech Pharmaceuticals, Inc., a global specialty pharmaceutical and medical device company, discovers, develops, and markets technologies and medical products primarily for local diseases or for complications associated with medical device implants, surgical interventions, and acute injury.

*********************************************************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

drstbc

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. DrStockPick.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold DrStockPick.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://drstockpick.com/disclaimer) .Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (OTCPK:CRWE) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (OTCPK:CRWE), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (OTCPK:CRWE) advertises for a particular client, Crown Equity Holdings Inc. (OTCPK:CRWE) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (OTCPK:CRWE), if paid in stock, can and may sell those securities during the advertising period.